ELACOI (Lopinavir/ritonavir), 2020 NCT04252885
umifenovir (arbidol) (n=35) vs. lopinavir/ritonavir (n=34)
randomized controlled trial
some concerns about risk of bias
Umifenovir
Arbidol (100mg) (oral, 200mg TID for 7-14 days)
Lopinavir/ritonavir
Lopinavir (200mg) boosted by ritonavir (50mg) (orally administed, twice daily, 500 mg, each time for 7-14 days).
3 arms : lopinavir/ritonavir; arbidol and standard care
COVID-19 mild to moderate
Open-label
China, single center
No deaths occurred.
Yethindra, 2020 None
umifenovir (arbidol) (n=15) vs. standard of care (n=15)
randomized controlled trial
high risk of bias
Umifenovir
600mg/d: orally administered, 200 mg three times per day for 1–5 days
Standard of care
Antivirals, antibiotics, immunoglobulin, and corticosteroids.
Standard of care in both groups.
COVID-19 mild to moderate
Age: 18-60
Not specified.
Single center, City Clinical Hospital in Bishkek, Kyrgyzstan.
Blindness unclear.